120 related articles for article (PubMed ID: 32931739)
21. Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.
Jia J; Li F; Tang XS; Xu S; Gao Y; Shi Q; Guo W; Wang X; He D; Guo P
Oncotarget; 2016 Jun; 7(25):37868-37881. PubMed ID: 27191265
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.
Lin PC; Chiu YL; Banerjee S; Park K; Mosquera JM; Giannopoulou E; Alves P; Tewari AK; Gerstein MB; Beltran H; Melnick AM; Elemento O; Demichelis F; Rubin MA
Cancer Res; 2013 Feb; 73(3):1232-44. PubMed ID: 23233736
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
[TBL] [Abstract][Full Text] [Related]
24. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
25. [The mechanisms of prostate cancer progression through androgen receptor].
Goto Y; Sakamoto S; Ichikawa T
Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
[TBL] [Abstract][Full Text] [Related]
26. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
27. Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.
Coulter JB; Easwaran H
PLoS Biol; 2023 Apr; 21(4):e3002081. PubMed ID: 37104249
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth.
Mygatt JG; Singhal A; Sukumar G; Dalgard CL; Kaleeba JA
Cancer Res; 2013 Sep; 73(18):5695-708. PubMed ID: 24005834
[TBL] [Abstract][Full Text] [Related]
29. Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.
Ito S; Ueda T; Ueno A; Nakagawa H; Taniguchi H; Hongo F; Kamoi K; Okihara K; Kawauchi A; Miki T
FEBS J; 2014 Oct; 281(19):4506-18. PubMed ID: 25132193
[TBL] [Abstract][Full Text] [Related]
30. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
[TBL] [Abstract][Full Text] [Related]
31. Epidaurus: aggregation and integration analysis of prostate cancer epigenome.
Wang L; Huang H; Dougherty G; Zhao Y; Hossain A; Kocher JP
Nucleic Acids Res; 2015 Jan; 43(2):e7. PubMed ID: 25378314
[TBL] [Abstract][Full Text] [Related]
32. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.
Larsson P; Syed Khaja AS; Semenas J; Wang T; Sarwar M; Dizeyi N; Simoulis A; Hedblom A; Wai SN; Ødum N; Persson JL
Int J Cancer; 2020 Mar; 146(6):1686-1699. PubMed ID: 31381135
[TBL] [Abstract][Full Text] [Related]
33. Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.
Zheng N; Wang L; Hou Y; Zhou X; He Y; Wang Z
Cell Cycle; 2018; 17(21-22):2460-2473. PubMed ID: 30394832
[TBL] [Abstract][Full Text] [Related]
34. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
35. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
36. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
37. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
38. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
40. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
